Biotech Rising | GenomeWeb

Biotech Rising

In 2014, the top six best-selling drugs will be biotech products, says EvaluatePharma, a healthcare analysis company. Of the top 100, they say biotech drugs will account for half. Evaulate predicts that the number one drug in five years will be Roche's Avastin, followed by Abbott's Humira, Roche's Rituxan, Wyeth's Enbrel, Sanofi-Aventis' Lantus, and Roche's Herceptin, according to Reuters.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.